Hamilton Wealth LLC Purchases New Position in Zimmer Biomet Holdings, Inc. $ZBH

Hamilton Wealth LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 7,494 shares of the medical equipment provider’s stock, valued at approximately $678,000.

Several other hedge funds also recently made changes to their positions in the company. Main Management ETF Advisors LLC lifted its holdings in shares of Zimmer Biomet by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares during the last quarter. Citizens National Bank Trust Department grew its stake in Zimmer Biomet by 17.6% during the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares during the last quarter. Independence Bank of Kentucky increased its position in Zimmer Biomet by 9.7% during the fourth quarter. Independence Bank of Kentucky now owns 1,633 shares of the medical equipment provider’s stock worth $147,000 after buying an additional 145 shares during the period. LOM Asset Management Ltd increased its position in Zimmer Biomet by 21.5% during the fourth quarter. LOM Asset Management Ltd now owns 830 shares of the medical equipment provider’s stock worth $75,000 after buying an additional 147 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in Zimmer Biomet by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after buying an additional 152 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 1.5%

NYSE:ZBH opened at $97.23 on Thursday. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. The stock’s 50 day simple moving average is $88.47 and its 200-day simple moving average is $89.81. The firm has a market cap of $18.81 billion, a P/E ratio of 25.26, a PEG ratio of 2.82 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion during the quarter, compared to the consensus estimate of $2.07 billion. During the same period last year, the company earned $1.81 earnings per share. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 24.94%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wells Fargo & Company decreased their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, April 29th. Barclays cut their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. Robert W. Baird set a $92.00 price target on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Stifel Nicolaus decreased their price target on shares of Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a research note on Wednesday, April 29th. Finally, Zacks Research downgraded shares of Zimmer Biomet from a “hold” rating to a “strong sell” rating in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, twelve have assigned a Hold rating and four have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $102.00.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of Zimmer Biomet stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the sale, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. The trade was a 15.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: UBS initiated coverage with a Buy rating and a $115 price target, implying substantial upside from recent trading levels. The firm cited Zimmer Biomet’s growth prospects and innovation, supporting optimism about its competitive position. Benzinga coverage
• Positive Sentiment: Recent coverage highlighted stronger quarterly revenue and described Zimmer Biomet as a top performer among diversified surgical-equipment companies. The company’s latest reported quarter also exceeded expectations, with earnings per share of $2.09 versus the $1.86 consensus and revenue of $2.09 billion versus $2.07 billion expected.
• Positive Sentiment: The stock is benefiting from renewed market confidence, with investors watching whether demand for orthopedic products, including knee and hip implants and robotic-assisted surgery systems, can support continued growth. Zimmer Biomet Gains Fresh Market Confidence
• Neutral Sentiment: Zimmer Biomet is approaching its second-quarter earnings release. Expectations call for modest revenue growth, making trends in knees, hips and surgical robotics especially important for the next market reaction. Zimmer Biomet Q2 Earnings Preview
• Negative Sentiment: Zacks Research downgraded the shares from Hold to Strong Sell, contrasting sharply with UBS and signaling concerns about valuation or the company’s growth outlook.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.